|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
To investigate the pharmacokinetic and pharmacodynamic properties of artesunate (ARTS) and its active metabolite dihydroartemisinin (DHA) in Plasmodium vivax infections, 12 male Vietnamese adults with slide-positive vivax malaria received either intravenous ARTS (120 mg; group 1) or oral ARTS (100 mg; group 2) with the alternative preparation given 8 hr later in a randomized, open, cross-over study. Following intravenous injection, ARTS had a peak plasma drug concentration (Cmax) of 35.6 microM (13.7 mg/L), an elimination half-life (t1/2) of 2.2 min, a clearance (CL) of 3.0 L/hr/kg, and a volume of distribution (V) of 0.16 L/kg. Dihydroartemisinin had a Cmax of 7.7 microM (2.2 mg/L), a tmax of 8 min, a t1/2 of 37 min, an apparent CL of 1.1 L/hr/kg, and an apparent V of 0.9 L/kg. Following oral ARTS, the mean relative bioavailability of DHA was 85%, the Cmax was 3.0 microM (0.85 mg/L), the tmax was 75 min, and t1/2 was 40 min. The mean time to 50% reduction in the parasite count (PCT50) and median fever clearance time were 3 hr and 16 hr, respectively. Following intravenous ARTS (group 1), the PCT50 for total parasites, rings, trophozoites, and gametocytes was 3.3 hr, 3.2 hr, 4.0 hr, and 3.6 hr, respectively. This study confirms that ARTS is effective against P. vivax, with rapid clearance of sexual and asexual forms of the parasite. Artesunate is a suitable initial treatment for vivax malaria, or when the plasmodial species cannot be reliably identified.
This article has been cited by other articles:
![]() |
Q. Li, L. R. Cantilena, K. J. Leary, G. A. Saviolakis, R. S. Miller, V. Melendez, and P. J. Weina Pharmacokinetic Profiles of Artesunate After Single Intravenous Doses at 0.5, 1, 2, 4, and 8 mg/kg in Healthy Volunteers: A Phase I Study Am J Trop Med Hyg, October 1, 2009; 81(4): 615 - 621. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Keiser, M.-S. Gruyer, N. Perrottet, B. Zanolari, T. Mercier, and L. Decosterd Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica J. Antimicrob. Chemother., March 1, 2009; 63(3): 543 - 549. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bennett, Y. Si, T. Steinbach, J. Zhang, and Q. Li Pharmacokinetic and Pharmacodynamic Evaluation of Intramuscular Artesunate in Healthy Beagle Dogs Am J Trop Med Hyg, July 1, 2008; 79(1): 36 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. LI, L. H. XIE, A. HAEBERLE, J. ZHANG, and P. WEINA THE EVALUATION OF RADIOLABELED ARTESUNATE ON TISSUE DISTRIBUTION IN RATS AND PROTEIN BINDING IN HUMANS Am J Trop Med Hyg, November 1, 2006; 75(5): 817 - 826. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Li, L. H. Xie, Y. Si, E. Wong, R. Upadhyay, D. Yanez, and P. J. Weina Toxicokinetics and Hydrolysis of Artelinate and Artesunate in Malaria-Infected Rats International Journal of Toxicology, July 1, 2005; 24(4): 241 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Karunajeewa, K. F. Ilett, K. Dufall, A. Kemiki, M. Bockarie, M. P. Alpers, P. H. Barrett, P. Vicini, and T. M. E. Davis Disposition of Artesunate and Dihydroartemisinin after Administration of Artesunate Suppositories in Children from Papua New Guinea with Uncomplicated Malaria Antimicrob. Agents Chemother., August 1, 2004; 48(8): 2966 - 2972. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tjitra, J. Baker, S. Suprianto, Q. Cheng, and N. M. Anstey Therapeutic Efficacies of Artesunate-Sulfadoxine-Pyrimethamine and Chloroquine-Sulfadoxine-Pyrimethamine in Vivax Malaria Pilot Studies: Relationship to Plasmodium vivax dhfr Mutations Antimicrob. Agents Chemother., December 1, 2002; 46(12): 3947 - 3953. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. F. Ilett, B. T. Ethell, J. L. Maggs, T. M. E. Davis, K. T. Batty, B. Burchell, T. Q. Binh, L. T. A. Thu, N. C. Hung, M. Pirmohamed, et al. Glucuronidation of Dihydroartemisinin in Vivo and by Human Liver Microsomes and Expressed UDP-Glucuronosyltransferases Drug Metab. Dispos., September 1, 2002; 30(9): 1005 - 1012. [Abstract] [Full Text] |
||||
![]() |
S. Krishna, T. Planche, T. Agbenyega, C. Woodrow, D. Agranoff, G. Bedu-Addo, A. K. Owusu-Ofori, J. A. Appiah, S. Ramanathan, S. M. Mansor, et al. Bioavailability and Preliminary Clinical Efficacy of Intrarectal Artesunate in Ghanaian Children with Moderate Malaria Antimicrob. Agents Chemother., February 1, 2001; 45(2): 509 - 516. [Abstract] [Full Text] |
||||
![]() |
P. Newton, Y. Suputtamongkol, P. Teja-Isavadharm, S. Pukrittayakamee, V Navaratnam, I. Bates, and N. White Antimalarial Bioavailability and Disposition of Artesunate in Acute Falciparum Malaria Antimicrob. Agents Chemother., April 1, 2000; 44(4): 972 - 977. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |